drugset
drugset / Trial / NCT00277043

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

NCT00277043 ↗

Phase 3 Completed 200 enrolled New Mexico Cancer Research Alliance
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study are to determine whether a test dose program for taxanes will reduce the rate and/or severity of hypersensitivity reactions (HSR); and to determine whether a test dose program for taxanes will result in cost reduction due to decreased drug wastage.

Timeline

Start
2002-06
Primary completion
2004-07
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 1 mg Intravenous
Subject Paclitaxel Small molecule 1 mg Intravenous

Indications

No indication recorded.